AUTHOR=Crossen Stephanie S. , Romero Crystal C. , Lewis Carrie , Glaser Nicole S. 

TITLE=Remote glucose monitoring is feasible for patients and providers using a commercially available population health platform

JOURNAL=Frontiers in Endocrinology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1063290

DOI=10.3389/fendo.2023.1063290

ISSN=1664-2392

ABSTRACT=<sec><title>Objective</title><p>Remote patient monitoring (RPM) holds potential to enable more individualized and effective care for patients with type 1 diabetes (T1D), but requires population analytics to focus limited clinical resources on patients most in need. We explored the feasibility of RPM from patient and provider standpoints using a commercially available data analytic platform (<italic>glooko</italic> Population Health) among a cohort of youth with T1D.</p></sec><sec><title>Study design</title><p>Patients aged 1-20 years with established T1D (≥12 months) and CGM use (≥3 months) were recruited to participate. Participants’ CGM devices were connected to the <italic>glooko</italic> app and linked to the research team’s <italic>glooko</italic> account during a one-month baseline period. This was followed by a six-month intervention period during which participants with &gt;15% of glucose values &gt;250 mg/dl or &gt;5% of values &lt;70 mg/dl each month were contacted with personalized diabetes management recommendations. Participants were surveyed about their experiences, and effects on glycemic control were estimated <italic>via</italic> change in glucose management indicator (GMI) generated from CGM data at baseline and completion. Changes in time spent within various glucose ranges were also evaluated, and all glycemic metrics were compared to a non-randomized control group <italic>via</italic> difference-in-difference regression, adjusting for baseline characteristics.</p></sec><sec><title>Results</title><p>Remote data-sharing was successful for 36 of 39 participants (92%). Between 33%-66% of participants merited outreach each month, and clinician outreach required a median of 10 minutes per event. RPM was reported to be helpful by 94% of participants. RPM was associated with a GMI change of -0.25% (<italic>P</italic>=0.047) for the entire cohort, and stratified analysis revealed greatest treatment effects among participants with baseline GMI of 8.0-9.4% (GMI change of -0.68%, <italic>P</italic>=0.047; 19.84% reduction in time spent &gt;250 mg/dl, <italic>P</italic>=0.005).</p></sec><sec><title>Conclusions</title><p>This study demonstrates the feasibility of RPM for patients with T1D using a commercially available population health platform, and suggests that RPM with clinician-initiated outreach may be particularly beneficial for patients with suboptimal glycemic control at entry. However, larger randomized studies are needed to fully explore the glycemic impact of RPM.</p></sec><sec><title>Clinical trial registration</title><p><uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04696640" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04696640</uri>, identifier NCT04696640.</p></sec>